Thank you very much for the question.
Definitely one of the challenges has been the paucity of data. At the beginning, we often don't have a lot of data. We have the clinical trials, but they are done in specific populations in relatively small numbers. We have to make our best recommendations with the available information, and then continue to monitor the ongoing information that comes from real-world use—effectiveness trials and safety trials in the real world. Then we incorporate that back into our recommendations and revise them if needed.
It has been an ongoing iterative process of trying to make the best recommendations with the available information and then staying on top of all the evolving information and modifying as needed.